ESTABLISHMENT LABS INC (ESTA)
Health Care · Medical Devices (Aesthetics) · NASDAQ
Establishment Labs is a medical technology company advancing women's health through its next-generation Motiva breast implant technology and aesthetic surgical solutions.
What ESTABLISHMENT LABS INC does
Establishment Labs is a medical technology company focused on women’s health, specifically within the breast aesthetics and reconstructive surgery market. The company develops and markets a portfolio of innovative breast implants, including its flagship Motiva Implants line, alongside other related surgical technologies and planning software.
Themes: women's health, aesthetic surgery, breast implants, medtech
Fundamentals
- Price$72.67 as of 2026-08-21 close
- Market cap$2.2B as of 2026-08-21
- 1-year return+81.7% 2025-08-21 close $40.00 → 2026-08-21 close $72.67
- P/En/a negative earnings
- Net margin-19.1% as of 2026-08-24
- Gross margin+70.1% as of 2026-08-24
- ROE-225.9% as of 2026-08-24
- Debt / equity17.58 as of 2026-08-24
- Revenue growth (YoY)+34.9% as of 2026-08-24
- Revenue CAGR (3y)+9.3% SEC XBRL
- Beta1.07 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ESTA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ESTA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
51.5 #696 of 1,704 scored · #123 of 240 in Health Care
Volume and participation 82nd: trading volume is about normal versus its 30-day average; catalysts 81st: the analyst consensus rating has improved toward "buy" since the prior reading; weakest is trend 26th: it is trading 15.6% below its 50-day average, the short-term trend line.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How ESTABLISHMENT LABS INC looks technically
ESTABLISHMENT LABS INC (ESTA) is trading 0.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 272 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 25.5% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 0.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $86.06 | $86.06 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $72.44 | $72.44 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 81.33. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 272 trading days ago — a "golden cross", a bullish long-term signal | 272 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.3% above | +0.3% |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 26.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 33.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($71.01 to $96.62) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 6.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $97.59 | $97.59 |
|---|---|---|
| From the 52-week high | it is 25.5% below its 52-week high (its highest price of the past year) | -25.5% |
| Above the 52-week low | it is 98.9% above its 52-week low (its lowest price of the past year) | +98.9% |
| Below the 52-week high | it is 25.5% below its highest point of the past year | 25.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $97.59 (set on 2026-08-03) | $97.59 |
| Given back of the 52-week move | over the past year its closes ranged ($36.84 to $95.65), and it has given back roughly a third of its rise from last year’s low — 39% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $57.42 to $59.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.1% |
| From the all-time high | it is 25.5% below its all-time high | -25.5% |
| Nearest price level | it is trading 2.2% below a resistance level at $74.29 — a price it turned at four times since 2026-01-09, most recently on 2026-08-11. Since 2024-08-21 it has 15 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.2% |
| All-time low | its lowest closing price on record is $7.56 (set on 2020-03-18) | $7.56 |
| Above the all-time low | it is 861.2% above its all-time low | +861.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.09 between its high and its low — about 5.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.09 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $65.44 and $99.40 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $65.44 – $82.42 – $99.40 |
| Typical daily range (% of price) | its price moves about 5.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.6% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges above its 200-day average price (0.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.17× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.28 toward buy |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.6% gap up opened on 2026-08-13 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.4 percentage points (the stock lost 24.0% while the market gained 2.3%) | -26.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.1 percentage points (the stock gained 2.0% while the market gained 3.1%) | -1.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 15.4 percentage points (the stock lost 4.4% while the market gained 11.1%) | -15.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 61.2 percentage points (the stock gained 81.7% while the market gained 20.5%) | +61.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 12.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -5.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $75.32 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -3.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is under water. That average is $76.02 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -4.4% |
Price levels it has turned at before
ESTA last closed at $72.67 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $74.29 | Resistance | 2.2% above the last close | turned there four times · 2026-01-09 to 2026-08-11 |
| $68.93 | Support | 5.1% below the last close | turned there four times · 2025-11-10 to 2026-04-22 |
| $66.08 | Support | 9.1% below the last close | turned there three times · 2026-02-06 to 2026-06-02 |
| $64.62 | Support | 11.1% below the last close | turned there twice · 2026-02-24 to 2026-05-15 |
| $83.58 | Resistance | 15.0% above the last close | turned there twice · 2026-02-25 to 2026-07-14 |
| $97.29 | Resistance | 33.9% above the last close | turned there twice · 2026-07-21 to 2026-08-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $81.33.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $42.89 and $57.57 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $81.33.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$102.44 range $92.00 – $117.00; median $105.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ESTA
- Consensus EPS estimate-$0.23 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and uncertainty regarding achieving/maintaining profitability.","Dependency on the commercial success of the Motiva Implants product line.","Significant regulatory risks and potential for supply chain disruptions from single-source suppliers."]
What changed in the latest 10-Q
AI-assisted comparison of ESTA's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) references Form 10-K filed February 27, 2026; older filing (2025-11-07) references Form 10-Q
- Newer filing adds leadership transition: Raj Denhoy moved to SVP Global Strategy, Cassandra Harris appointed SVP and CFO effective March 9, 2026
- Newer filing adds financing activity: April 30, 2026 Amended and Restated Credit Agreement with Oaktree Fund Administration providing up to $300 million in term loans, with $265 million first tranche advanced
- Newer filing reports Q1 2026 (three months ended March 31, 2026) results: revenue $59.9 million, net loss $13.4 million, accumulated deficit $509.1 million, cash balance $68.1 million
- Newer filing adds three-month period comparison table with detailed revenue, cost, and expense breakdowns for Q1 2026 vs Q1 2025
- Newer filing adds gross margin analysis showing 70.7% for Q1 2026 vs 67.2% for Q1 2025 with explanations
- Newer filing specifies revenue increases: $13.5 million in U.S., $5.0 million internationally (Asia-Pacific and Latin America)
- Removed:
- Older filing's statement that Motiva Implants 'are commercially available in over 90 countries' removed from newer filing overview
- Older filing's reference to 'published third-party registries and data' removed from newer filing
- Older filing's mention of 'other complementary products and services' to enhance patient outcomes removed from newer filing
- Older filing's reference to Motiva Flora SmoothSilk Tissue Expander 510(k) clearance in October 2023 removed from newer filing overview
- Older filing's financial highlights for nine months ended September 30, 2025 removed; newer filing shows only Q1 2026 and Q1 2025
- Older filing's accumulated deficit figure of $493.1 million (as of September 30, 2025) superseded by $509.1 million (as of March 31, 2026)
- Older filing's cash balance of $70.6 million (September 30, 2025) superseded by $68.1 million (March 31, 2026)
- Entire 'Recent Developments' section from older filing (October 2025 publication announcement, May 2025 CEO appointment, March 2025 partnership, etc.) removed from newer filing's Recent Developments, replaced with February 2026 leadership transition and April 2026 financing
- Older filing's detailed financing activities section (RTW inventory funding agreement, November 2024 securities offering) not present in newer filing excerpt
- Reworded:
- Older filing states Motiva study results are 'post-market surveillance data (which was not generated in connection with a United States Food and Drug Administration pre-market approval study)'; newer filing simplifies to '5-year results from our Motiva U.S. IDE study as well as our patient and practitioner reported post-market surveillance data'
- Older filing references 'Risk Factors' in 'Part II, Item 1A of this Quarterly Report'; newer filing references 'Part I, Item 1A of our Form 10-K'
- Older filing describes adverse events as 'safety related reoperations'; newer filing uses 'implant-related reoperations'
- Newer filing adds specific statement: 'We believe these proprietary technologies that differentiate our Motiva Implants result in improved safety and aesthetic outcomes and thus drive our revenue growth'
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs. nine-month period ended September 30, 2025), making some comparisons not directly equivalent
- The older filing excerpt is truncated at the Financing Activities section and does not include the complete MD&A
- Financial metrics are for different time periods and thus not directly comparable year-over-year
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($5M) — 1 selling insider
- Last 180 days0 buys · 22 sells ($33M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-05-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ESTA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ESTA had 4,346,413 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ESTA had 14.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.94 days to cover at the same settlement.
- Reported short interest (shares) 4,346,413
- Short interest (% of shares outstanding) 14.6%
- Prior settlement (shares) 4,484,589
- Reported change -3.08%
- Days to cover (reported) 9.94
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ESTA vs…
Frequently asked questions
What does ESTABLISHMENT LABS INC (ESTA) do?
Establishment Labs is a medical technology company focused on women’s health, specifically within the breast aesthetics and reconstructive surgery market. The company develops and markets a portfolio of innovative breast implants, including its flagship Motiva Implants line, alongside other related surgical technologies and planning software.
What sector is ESTABLISHMENT LABS INC (ESTA) in?
ESTABLISHMENT LABS INC (ESTA) is classified in the Health Care sector. Its industry is Medical Devices (Aesthetics). It trades on NASDAQ.
Who are ESTABLISHMENT LABS INC's (ESTA) competitors?
Notable peers of ESTABLISHMENT LABS INC (ESTA) include Johnson & Johnson (Mentor), AbbVie (Allergan Aesthetics) and Sientra. This peer set is informational only — not financial advice.
Is ESTABLISHMENT LABS INC (ESTA) overbought or oversold right now?
ESTABLISHMENT LABS INC (ESTA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ESTA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.